Exhibit 10.14License and Development Agreement“Agreement”betweenNLS-1 Pharma AGAlter Postplatz 26370 StansSwitzerland“Licensor” / “NLS”andEurofarma Laboratórios S.A.Avenida Vereador José Diniz 346504603-003 São PauloBrazil“Licensee” / “Eurofarma”(Licensor and Licensee each a ʺPartyʺcollectively the ʺPartiesʺ)regardingNolazol (Mazindol CR) in ADHD Latin AmericaSource: NLS PHARMACEUTICS LTD., F-1, 2/28/2020License and Development AgreementTable of ContentWHEREAS11.Definitions12.Grant of License42.1.Grant of rights42.2.Restrictions43.License Fees and Milestone Payments53.1.Upfront Payment53.2.Milestone payments53.3.Royalties63.4.Reports63.5.Records and Audits63.6.Payment Terms74.Business Plan75.Development Work86.Further Development Work87.Brand Name and Trademarks98.Labelling and Packaging99.Regulatory Obligations and Procedures109.1.Regulatory Obligations and Procedures in General109.2.Notifications109.3.Regulatory Obligations of Licensee109.4.Regulatory Obligations of Licensor109.5.Pharmacovigilance1110.Cooperation and Joint Project Steering Committee1110.1. Cooperation1110.2. Transfer of Know-how1110.3. Joint Steering Committee1211.Commercialization1212.Supply1313.Property rights to Intellectual Property1314.Prosecution of Infringements of Intellectual Property1314.1. Notice1314.2. Action1314.3. Information1415.Representations and Warranties1415.1. Licensor Representations and Warranties1415.2. Licensee Representations and Warranties1415.3. Other Representations and Warranties1516.Liability and Limitations1517.Indemnities1617.1. Indemnities by the Licensor1617.2. Indemnities by the Licensee1617.3. Third party claims1618.Confidentiality1718.1. Confidentiality Obligations1718.2. Exceptions to Obligations1718.3. Survival of Confidentiality Obligations18iSource: NLS PHARMACEUTICS LTD., F-1, 2/28/2020License and Development Agreement19.Term and Termination1819.1. Term1819.2. Termination for Change of Control1819.3. Termination for Bankruptcy, Liquidation and similar proceedings1819.4. Early Termination for Material Breach1819.5. Early Termination by the Licensor1919.6. Early Termination by the Licensee1919.7. Consequences of Expiration or Termination2020.General Provisions2020.1. Amendments2020.2. Notices2020.3. Severability / Good Faith2020.4. No Waiver2120.5. No Assignment2120.6. Appendices2120.7. Public Announcements2121.Governing Law and Jurisdiction21Table of Appendices23Appendix A [Template for Licensee Reports]24Appendix B Preliminary Business Plan25Appendix C Purpose of the JSC pre and post MA No such appendix completed by the parties.iiSource: NLS PHARMACEUTICS LTD., F-1, 2/28/2020License and Development AgreementWHEREASA.NLS carries on the business of researching, developing and manufacturing certain pharmaceutical products and is the legal and beneficialowner of certain Intellectual Property, including Patents, Know-how and other materials (all words with capital letters are defined below);B.Eurofarma is a pharmaceutical company with expertise in researching, developing, manufacturing, marketing and sales of pharmaceuticalproducts, including products in the Field, and has a distribution network throughout Latin America;C.Eurofarma wishes to receive an exclusive license from NLS to register, import, export, store, handle, commercialize, have commercialized,promote, have promoted, distribute, have distributed, sell and have sold the Licensed Product in the Territory, and NLS wishes to grant arespective license on the terms and conditions set out in this Agreement;D.The Parties acknowledge that further development of the Products will be necessary to develop the required Dossier as defined hereunder forobtaining Marketing Authorisation(s) in the Territory and wish to collaborate on the further development of the Products.NOW, THEREFORE, the Parties agree as follows:1.DefinitionsWhen used in this Agreement in capital letters, the terms and abbreviations set forth below, whether used in the singular or plural, shallhave the following meaning:Affiliatesmeans any company, enterprise, corporation or business entity which controls, is controlled by, or is under common controlwith, either the Licensor or Licensee. For this purpose, “control” shall mean the possession, directly or indirectly, of thepower to direct or cause the direction of the management and policies of an entity, whether through holding a majority of thevoting rights of the entity, by contract or otherwise.Agreement shall mean this Agreement, including all of its Appendices.Appendixshall mean any appendix to this Agreement.Articleshall mean an article of this Agreement.Change ofControlshall mean any merger, consolidation or acquisition of a Party with, by or into another corporation, entity or person; or anychange in the ownership of more than fifty percent (50%) of the voting capital stock or actual control over the voting rightsin one or more related transactions.ConfidentialInformationshall have the meaning set forth in Article 18.DevelopedIntellectualPropertyshall mean any and all changes, additional Know-how, improvements and inventions relating to the Intellectual Property(such as, without limitation, method of use patents) made after the Effective Date of this Agreement.1Source: NLS PHARMACEUTICS LTD., F-1, 2/28/2020License and Development AgreementDistributor shall mean a company appointed by Licensee and agreed by Licensor in a country of the Territory for the import, selling,promotion and distribution of the Licensed Product in such country of the Territory.Dossiershall mean the registration file for the Licensed Product (which will be developed based on the Know-how and the IntellectualProperty Rights) including any data, studies, documents, reports, correspondence with regulatory authorities, approvals andinformation that is necessary for obtaining and maintaining one or several Marketing Authorizations in the Territory.EffectiveDateshall be the date of the last signature on the last page of this Agreement.Fieldshall mean the diagnosis, prevention, and treatment of DSM-V Attention Deficit and Hyperactivity Disorder (ADHD) inchildren, adolescents and adult populations.IndemnifiedPartyshall have the meaning set forth in Article 17.3.IntellectualPropertyshall mean Intellectual Property Rights and Know-how.IntellectualPropertyRightsshall mean with respect to the Licensed Product (as defined hereunder) any and all patents, copyright (including software),rights under data exclusivity laws, property rights in biological or chemical materials, names, trademarks, extension of theterms of any such rights (including supplementary protection certificates), applications for and the right to apply for any ofthe foregoing registered property rights, and similar or analogous rights anywhere in the world.JointSteeringCommittee/ JSCshall have the meaning set forth in Article 10.3 of this Agreement.Know-howshall mean with respect to the Licensed Product (as defined hereunder), all materials, laboratory, pre-clinical and clinical data,knowhow, trade secrets and all other scientific, technical, including manufacturing or regulatory information, patentable orotherwise, developed, applied or acquired by NLS which relates to the identification, characterization, expression, synthesis,use, or production of the Licensed Product and which is reasonably useful or necessary to research, develop, use, make, havemade, import, distribute, offer for sale, and/or sell the Product.Launchshall mean the first commercial sale of a Licensed Product in a country of the Territory by the Licensee or an Affiliate of theLicensee or by a Distributor engaged by Licensee.LeadCountriesBrazil, Mexico and Argentina.Licenseshall have the meaning set forth in Article 2.1 of this Agreement.2Source: NLS PHARMACEUTICS LTD., F-1, 2/28/2020License and Development AgreementLicensedProductAny and all products that are manufactured, sold, or otherwise supplied by the Licensee (including any Affiliate orDistributor of the Licensee) and which incorporate, or their development makes use of, any Intellectual Property orDeveloped Intellectual Property.LicenseeKnow-howshall mean with respect to the Licensed Product (as defined hereunder) all know-how, trade secrets and scientific, technical,including manufacturing or regulatory information, developed, applied or acquired by Eurofarma which relates to theidentification, characterization, expression, synthesis, use, or production of the Licensed Product and which is reasonablyuseful or necessary to research, develop, use, make, have made, import, distribute, offer for sale, and/or sell the LicensedProduct.Lossesshall have the meaning set forth in Article 17.1 of this Agreement.MarketingAuthorisation/ MAin relation to the Licensed Product, shall mean those approvals necessary from one or more competent authorities in theTerritory for manufacturing, importing, marketing, distributing, offering for sale and/or selling the Licensed Product in oneor several countries of the Territory.Net Salesmeans the total of the gross invoice prices of Licensed Products sold or leased by the Licensee, an Affiliate, a Distributor,or any combination thereof, less the sum of the following actual and customary deductions where applicable and separatelylisted: cash, trade, or quantity discounts; sales, use, tariff, import/export duties or other excise taxes imposed on particularsales (in particular value-added tax); transportation charges; or credits to customers because of rejections or returns. Forpurposes of calculating Net Sales, transfers to an Affiliate or to a Distributor of Licensed Product under this Agreement for(i) end use (but not resale) by the Affiliate shall be treated as sales by Licensee at the list price of the Licensee in an arm-length transaction, or (ii) resale by an Affiliate shall be treated as sales at the list price of the Affiliate.Patentsshall mean Brazilian Patent Application No. BR 11 2018 068143 filed on September 6, 2018, and Mexican Patent ApplicationNo. MX/a/2018/010864 filed on September 7, 2018, covering multi-layered formulation of Mazindol, including all provisionalapplications, continuations, divisions, extensions, re-examinations, certificates, reissues and Supplementary ProtectionCertificates.Phase IIIClinical Trialshall mean a controlled clinical study of mazindol CR that aims to establish the therapeutic benefit and safety of mazindolCR in the Field in a larger patient sample in a manner sufficient to be included in the Dossier and obtain one or severalMarketing Authorisations to market such Licensed Product in the Territory.3Source: NLS PHARMACEUTICS LTD., F-1, 2/28/2020License and Development AgreementReport(s)shall have the meaning set forth in Article 3.4.Royalty / Royaltiesshall have the meaning set forth in Article 3.3.TerritoryThe countries of Latin AmericaTrademarksshall have the meaning set forth in Article 7.2.Grant of License2.1.Grant of rightsSubject to the conditions and limitations set forth in this Agreement, the Licensor hereby grants to the Licensee, and theLicensee hereby accepts, (i) an exclusive, fee-bearing, non-transferable distribution right of the Licensed Product in the Territoryduring the Term (the “Distribution”), (ii) an exclusive, royalty-free, non-transferable license to the Licensor’s Patents andTrademarks to register, import, export, store, handle, commercialize, have commercialized, promote, have promoted, distribute,have distributed, sell and have sold the Licensed Product during the Term, without the right to sublicense (the “License”), and(iii) an exclusive, royalty-bearing, non-transferable license to the Intellectual Property (except Patents and Trademarks ) and theDeveloped Intellectual Property and a right to obtain the technology transfer of the Know-How to manufacture the LicensedProduct in the Territory during the Term, pursuant to the conditions set forth in Article 2.3 below and elsewhere in thisAgreement (the “Technology Transfer”), all to register, import, export, store, handle, commercialize, have commercialized,promote, have promoted, distribute, have distributed, manufacture, have manufactured, sell and have sold the Licensed Productduring the Term, without the right to sublicense.2.2.RestrictionsLicensee may extend the rights granted herein to register, import, export, store, handle, commercialize, promote, distribute and sellto its Affiliates and to its Distributors, provided that Licensee shall first provide to Licensor a written assurance from each ofsuch Affiliate or Distributor to agree to be bound by, and to strictly comply with, all applicable terms, conditions, and obligationsin this Agreement towards Licensor.Licensee shall not be entitled to assign the License or any of its rights under this Agreement or to grant any sub-licenses.2.3.Technology TransferAfter Licensor and Licensee have agreed to move forward to the Technology Transfer phase, the Parties will execute a separateTechnology Transfer Agreement, which shall be at arms-length basis and pursuant to the conditions herein. For that purpose,Licensor hereby undertakes to transfer to Licensee all Know-how in order to enable Licensee to implement it in its plant toregister, import, export, store, handle, commercialize, have commercialized, promote, have promoted, distribute, have distributed,manufacture, have manufactured, sell and have sold the Licensed Product during the Term.Licensee undertake to use the transferred Know-how solely for the purposes and limits provided in this Agreement. For theavoidance of any doubt, the Know-how does not include Licensee Know-how Licensor shall render to Licensee all technicalassistance necessary to enable Licensee to fully implement the Technology Transfer phase in Licensee’s premises. The royaltiesprovided in this Agreement already includes such technical assistance, unless the Parties otherwise mutually and in good-faithagree. In such case, the Parties will provide in separate agreement the additional conditions for the Technology Transfer, whichshall be at arms-length basis.4Source: NLS PHARMACEUTICS LTD., F-1, 2/28/2020License and Development Agreement3.License Fees and Milestone Payments3.1.Upfront PaymentUpon signature of this Agreement and no later than 20 days following it, Eurofarma shall pay to NLS, for the rights pursuant toArticle 2.1(i), the non-refundable and non-deductible sum of USD 2’500’000 (in words: US dollars two and a half million).3.2.Milestone paymentsUpon achievement of each of the milestone events set out below, Eurofarma shall pay to NLS the non-refundable and non-deductible amounts set out below next to such milestone event:3.2.1.Clinical MilestonesUpon successful completion by NLS in the US of the Phase III Clinical Trial for the treatment of ADHD in adults(successful completion meaning reaching the primary endpoints of the respective study)USD500’000Upon successful completion by NLS in the US of the last Phase III Clinical Trial for the treatment of ADHD in children(successful completion meaning reaching the primary endpoints of the respective study)USD500’0003.2.2.Regulatory MilestonesUpon price approval of the Licensed Product in Brazil by the relevant agencyUSD 1’000’000Upon receipt of a MA by the relevant agency of the Licensed Product in any other country in the TerritoryUSD 1’000’0003.2.3.Sales Milestones (single payments)Upon reaching annual Net Sales of USD 10 millionUSD 1’000’000Upon reaching annual Net Sales of USD 50 millionUSD 2’000’000Upon reaching annual Net Sales of USD 75 millionUSD 4’000’000Upon reaching annual Net Sales of USD 100 millionUSD 6’000’0005Source: NLS PHARMACEUTICS LTD., F-1, 2/28/2020License and Development Agreement3.3.RoyaltiesFor the Technology Transfer and as applicable for the License granted by NLS to Eurofarma under article 2.1(iii) hereabove,Eurofarma shall pay to NLS royalty payments (the “Royalties”) on the annual Net Sales in the Territory according to the followingtable:Annual Net Sales in the Territory in USD:Royalty inPercent of NetSalesunder 10 million7%10 million to 20 million8%20 million to 30 million9%30 million and above10%Royalty payments shall be paid quarterly within thirty (45) days following the close of the calendar quarter.3.4.ReportsAfter the first commercial sale of a Licensed Product anywhere in the Territory, Eurofarma shall submit to Licensor quarterlyreports on or before 15 days after the last business day of the month following each quarter of the year, and this for each year.Each report (the “Reports”) shall cover Eurofarma’s (and each Affiliate’s, unless the Parties agree that such Affiliates shall submitits reports directly to Licensor) and Distributors’ last recently completed quarter and shall show:(i)the gross sales and Net Sales during the last recently completed quarterly period and the Royalties, in USD, payablewith respect thereto;(ii)the number of the Licensed Products sold in each country of the Territory;(iii)the method used to calculate the Royalties; and(iv)the exchange rates used to convert the country currency to USD, as applicable.The Licensee shall provide the above information using the form as shown in Appendix A and include information on the date ofthe first commercial sale of the Licensed Product in each country.If no sales of Licensed Product have been made by the Licensee during a reporting period, Licensee shall report such informationin the corresponding Report(s).3.5.Records and AuditsThe Licensee shall keep, and shall require its Affiliates and Distributors to keep, accurate and correct records of the LicensedProduct used and sold under this Agreement. Such records shall be retained by the Licensee for ten (10) years following a givenreporting period.6Source: NLS PHARMACEUTICS LTD., F-1, 2/28/2020License and Development AgreementSubject to a written advance notice of thirty (30) calendar days, all relevant records supporting the preparation of the Reportsshall be made available during normal business hours for inspection at the expense of Licensor by Licensor or by a selectedrepresentative of Licensor for the sole purpose of verifying the Reports and the accuracy of the payments made or due toLicensor under this Agreement. Such inspector shall not request any other documents or information other than these related tothis purpose as determined in its sole discretion and the Licensee shall have no obligation to provide the inspector or Licensorany documents or information not related thereto.In the event that any such inspection shows an underreporting and underpayment by the Licensee to Licensor under the termsof this Agreement in excess of one percent (1%) for any twelve-month (12-month) period, then Licensee shall pay the cost of theaudit as well as any additional sum that would have been payable to Licensor had the Licensee reported correctly, plus aninterest charge at a rate of ten percent (10%) per year. Such interest shall be calculated from the date the correct payment was dueto Licensor up to the date when such payment is actually made by the Licensee. For underpayment not in excess of one percent(1%) for any twelve-month (12-month) period, the Licensee shall pay the difference within thirty (30) days without having to payfor the inspection cost but with interest charge calculated as per the provisions of this Article.3.6.Payment TermsAll payments due to the Licensor according to this Agreement shall be in US dollar, unless the Parties mutually agree otherwise.All payments are exclusive of VAT and other applicable taxes. Royalties earned on Net Sales shall not be reduced by the Licenseefor any taxes, fees, or other charges imposed by the government of any country on the payment of royalty income, except that allpayments made by Licensee in fulfilment of the Licensors’ tax liability in any particular country may be credited against earnedRoyalties or fees due to the Licensor for that country. The Licensee shall pay all bank charges resulting from the transfer of suchRoyalty payments.Except for article 3.1 hereabove, payments shall be made by wire transfer to the bank nominated by Licensor, in maximum 45 daysafter the issuance by NLS of the corresponding invoices,In the event any payment due under this Agreement is not made at the agreed term and/or for the corresponding full amount, alate payment charge of ten percent (10 %) p.a. is due, calculated on a pro-rata basis of the number of days between the date atwhich the outstanding amount was due for payment to Licensor and the date is actually paid.For the payments under Article 2.1(iii) above, referred to in Article 3.3, Licensor understands that any such payments may onlybe remitted by Licensee after this (or a corresponding) Agreement has been recorded by the Brazilian Patent and TrademarkOffice (“INPI”) and registered by the Brazilian Central Bank (“Bacen”), as required by Brazilian law.4.Business PlanPrior to the signing of this Agreement, Eurofarma has prepared and presented to NLS a high-level business plan, focusing on the LeadCountries (the “Preliminary Business Plan” as per Appendix B).Following the signing of this Agreement and prior to the Launch in each of the Lead Countries, and in any other countries of theTerritories as applicable, Eurofarma shall present to NLS its business plan in such countries (the “Business Plan”) consistent withcommercially reasonable efforts to launch and market the Licensed Product in such countries of the Territory and consistent with thePreliminary Business Plan.7Source: NLS PHARMACEUTICS LTD., F-1, 2/28/2020License and Development AgreementEurofarma shall use reasonable commercial efforts to comply with the sales set out in the Preliminary Business Plan, and the Business Planmay be updated annually by Eurofarma based on updates on the clinical development timelines, market and economic changes and resultsfrom clinical trials, which shall be mutually accepted and agreed between the Parties. Except for critical changes in the assumptionsconsidered in the Preliminary Business Plan, the sales shall not vary substantially.5.Development WorkThe Parties acknowledge and agree that development work will need to be carried out in the US in order to seek a Marketing Authorizationof mazindol CR for use in the Field in the United States (the “Development Work”).The Development Work will in particular consist of, but not be limited to:a.the design, conduct and execution of pre-clinical studies and Phase I Clinical Trial for the End of Phase II Meeting by NLS as thesponsor (the “US Sponsor”) in the US in accordance with the guidance and requests from the US FDA;b.the design, conduct and execution of Phase III Clinical Trials by the US Sponsor in the US in accordance with the guidance andrequests from the US FDA;c.the development of the registration dossier which shall be submitted by NLS to the FDA to seek a marketing authorization ofNolazol (mazindol CR) for the treatment of ADHD in the US (the “FDA Dossier”).The Parties further acknowledge and agree that:i.such Development Work shall be carried out by NLS under its sole responsibility and its sole discretion as the US Sponsor;ii.NLS shall bear the costs of the Development Work it carries out in the US for the purpose of filing an NDA and seeking amarketing authorization in the US;iii.NLS shall share with Eurofarma the final reports of the planned studies in the Development Work as soon as available which shallbe only used by Eurofarma for the Dossier and for no other purposes. Such reports constitute Developed Intellectual Propertyand are the sole property and Confidential Information of Licensor.6.Further Development WorkThe Parties acknowledge and agree that further development work on the Licensed Product may have to be carried out in order to seekand obtain MA of the Licensed Product in certain of the countries of the Territory (the “Further Development Work”).The Parties acknowledge and agree that:i)NLS shall have sole responsibility and control of such Further Development Work, irrespective of whether it is carried by NLS assponsor, or delegated by NLS to Eurofarma in any countries of the Territory or to any other 3rd party at NLS sole discretionii)Eurofarma shall provide at its own costs timely input to NLS on the specific data and information not planned by NLS to beincluded in the FDA Dossier which are to be requested by the regulatory authorities of any of the Lead Countries to seek a MA inthe Lead Countries (the “US Supplemental Data”);8Source: NLS PHARMACEUTICS LTD., F-1, 2/28/2020License and Development Agreementiii)NLS shall use commercially reasonable efforts to generate the US Supplemental Data at a shared cost between the Parties whichshall be made available to Eurofarma for inclusion in the registration dossiers filed by Eurofarma to seek a MA;iv)If the regulatory authorities of any countries of the Territory request specific data to be generated locally in subjects of suchcountries in order to seek a MA, Eurofarma shall solely bear the respective costs of the studies needed to generate such data (the“Local Supplemental Data”);v)Eurofarma shall be responsible for the preparation and submission of the registration dossiers in the Lead Countries and in theother countries of the Territory seeking to obtain a MA in such countries;vi)Eurofarma shall be the responsible Party for the discussions with the regulatory health authorities or with the other relevantauthorities of such countries of the Territory involved in the MA process;vii)any intellectual property, know-how, trade secrets, data, processes whether patentable or not which may arise from the FurtherDevelopment Work and the Supplemental Data shall be solely owned by NLS and shall fall under NLS Intellectual PropertyRights and any other rights as the case maybe, except any information that is or becomes public (non-confidential) other than asa direct or indirect result of a disclosure by Licensee or any of its representatives. Licensee Knowhow shall belong to Licensee;viii)as set forth in Article 10.3 below a Joint Steering Committee shall be set-up. The JSC shall solely have an advisory role to theParties. NLS shall retain final responsibility for the design, conduct and execution of the Development Work and FurtherDevelopment Work.7.Brand Name and TrademarksThe brand name for the Licensed Product in the Territory shall be Nolazol (Brazilian trademark application No. 916475913 and in Mexicoand elsewhere in the Territory to be provided by Licensor, collectively referred to as “Trademark”) and may be modified by another namechosen and solely owned by the Licensor, subject to such modified name being communicated to Licensee no later than 6 months beforethe market launch of the License Product in Brazil. The Licensor shall be free to select and register any names and trademarks for theLicensed Product at its sole discretion. Such trademarks and names shall be prepared and owned by the Licensor at its expense. TheLicensor shall bear all costs associated with the use of such trademarks and names.During the entire validity of this Agreement, Licensor hereby grants to License an exclusive and royaltyfree right to use the Trademark inthe Territory. During any sell-off period the license shall be non-exclusive.8.Labelling and PackagingLicensee shall at its own expense create the labelling, localized product information and packaging for the Licensed Product. Licensor andLicensee shall cooperate in order to obtain the necessary regulatory and governmental approvals for such labelling and packaging.9Source: NLS PHARMACEUTICS LTD., F-1, 2/28/2020License and Development Agreement9.Regulatory Obligations and Procedures9.1.Regulatory Obligations and Procedures in GeneralThe Parties acknowledge that Marketing Authorisation(s) for the Licensed Product will have to be obtained for the purpose ofthis Agreement. The Parties will mutually agree on the regulatory pathway(s) to be used through the Joint Steering Committee.9.2.NotificationsEach of the Parties shall promptly notify the other party in writing of any technical or clinical advances, useful modifications, sideeffects or new government regulations relating to the Licensed Product that shall come to its knowledge.9.3.Regulatory Obligations of Licensee(i)Eurofarma shall own the MAs pertaining to the commercialization of the Licensed Product in the Field in the Territoryduring the term of this Agreement or until its termination prior to its term as set forth in Articles 19.2 to 19.6. Uponexpiration or termination, Eurofarma shall i) immediately transfer the MAs to the Licensor or to any other partydesignated by the Licensor and return all relevant documents prepared or submitted that are related to the MAs,including those documents, data or information generated post MA filings, in maximum 30 days after the notification oftermination; if the Licensor does not decide and inform within this period to whom the MAs and documents shall betransferred, then the Licensee shall have no obligation to keep them actives ii) shall forfeit its ownership of the MAs inany and all of the countries of the Territory and with other regulatory agencies, without any form of compensationexcept for the compensation under the conditions set forth in Article 19.2 below and, iii) shall have no further claims ofownership and nor any other claims related to the MAs.(ii)Eurofarma shall solely bear the costs related to the required regulatory procedures and for the MA and the MAapplication, grant, maintenance, update, variation, defence and renewal, as the case may be, in the Territory throughoutthe term of this Agreement.(iii)In advance of their use and/or submission, Eurofarma shall furnish NLS with copies of all material correspondence to besent to the competent regulatory authorities in the Territory, and all MA applications which are prepared for theLicensed Product. NLS shall have the right to comment and Eurofarma must comply with the requested changes by theNLS, provided that any such comments and/or changes are in compliance with the rules of the local and competentregulatory agencies.(iv)Subject to NLS prior written approval which may be granted at its own discretion and for its own reasons, Eurofarmamay conduct certain work pre MA approval or post MA approval and in that case Eurofarma agrees to share with NLSany data from laboratory, preclinical, clinical, chemistry, manufacturing and control studies conducted in support of itsregulatory filings for the development, approval, and marketing of the Licensed Product and after its marketing approvalas the case may be, should Eurofarma conduct any such work on its own. Any contribution of NLS to the costs of suchwork (that do not fall under 9.3 (ii)) (including, without limitation, translation of documents) shall be the exclusiveresponsibility of NLS.9.4.Regulatory Obligations of LicensorLicensor shall take all reasonable actions and render all reasonable assistance to help Licensee obtain and maintain the MAwhich are reasonably requested by the Licensee or required by the competent authorities in line with local requirements and/ornecessary to avoid the imposition of any restriction or condition under the MA by the competent authorities.10Source: NLS PHARMACEUTICS LTD., F-1, 2/28/2020License and Development AgreementLicensor shall provide the Licensee the Dossier, any updates and variations to the Dossier (such as monograph, method updatesor stability data, new manufacturer or API supplier) without undue delay when such additional data is available to the Licensor.In any event, Licensor understands and agrees that any variations and/or updates shall only be implemented by Licensee oncethis is permissible according to applicable regulatory provisions. In case the corresponding regulatory agency requests anyinformation on any updates and/or variations requested by NLS, the responsibility to provide such information shall be of NLS,and NLS shall be bound to any deadlines and other requirements posed by the regulatory agency.9.5.PharmacovigilanceThe Parties acknowledge that they may be required to submit adverse drug experience reports and supplemental information togovernmental agencies with respect to the Products.Eurofarma shall assume full responsibility for all post MA approval Pharmacovigilance activities in the Territory Each Party hasthe right to receive in good faith all the safety documents referring to the product filed by the other Party to regulatory authoritiesincluding PSURs (Periodic Safety Update Report), PBRER (Periodic Benefit Risk Evaluation Report), RMP (Risk Managementplans), but not limited to only these.Further, each Party agrees to report to the other Party any serious and unexpected adverse reaction with the use of mazindol CRin the Field within two business days of the initial receipt of a report or sooner if required for either Party to comply withregulatory requirements; and the Parties agree that the Licensee shall immediately report and notify in writing to NLS any adverseor suspected safety adverse events whether related or not to the Licensed Product (the “SAE’s” and the “SUSAR’s”). Partiesshall then immediately set a Pharmacovigilance meeting or conference call to review such case and decide on course of action, infull compliance with their obligations under relevant laws and guidelines.Prior to the first commercial sale of the Licensed Product in the Territory, the Parties will negotiate and enter into a Safety DataExchange Agreement further specifying the mutual obligations of the parties related to pharmacovigilance, to the extent that theydeem this to be required under GCP’s, applicable laws or other regulatory obligations, necessary or useful.10.Cooperation and Joint Project Steering Committee10.1.CooperationThe parties agree to cooperate in good faith with regard to all issues pertaining to the development of US Supplemental Data andLocal Supplemental Data, to regulatory matters concerning the Licensed Product in any countries of the Territories, and the pre-marketing and commercial activities of the Licensed Products in countries of the Territories, as necessary and applicable.10.2.Transfer of Know-howEach Party shall, at the other Party’s request, transfer to the other Party any and all Know-how relating to each Licensed Productthat the other Party reasonably needs in order to perform its obligations or exploit its rights under this Agreement. Each Partyshall use such Know-how solely for the purpose of performing its obligations or exploiting its rights under this Agreement.11Source: NLS PHARMACEUTICS LTD., F-1, 2/28/2020License and Development Agreement10.3.Joint Steering CommitteeWithin 60 business days following the execution of this Agreement, the Parties shall set-up a joint project steering committee (the“Joint Steering Committee” or “JSC”), by each Party designating its initial members to serve on the Joint Steering Committeeand notifying the other Party of its dates of availability for the first meeting of the Joint Steering Committee.The Joint Steering Committee shall be composed of senior members or representatives of NLS and Eurofarma with relevantcompetences in clinical development, regulatory, marketing and commercial matters and shall consist of an equal number ofmembers appointed by each Party. The Parties will discuss und agree on the appropriate number of members. Each Party maychange its members from time to time.The purpose of the Joint Steering Committee, by sharing the respective competences and experiences of the Parties shall be to asdetailed below:i)facilitate the preparation of the Dossiers, identify data which may be necessary to be generated for the filings of the MAapplications by the Licensee, in particular in the Lead Countriesii)agree on respective activities and responsibilities of the Parties pre-MA and post MA, in particular regarding regulatory,safety and clinical development matters pre-MA, label changes and other post MA mattersiii)align the Parties on pricing strategy, sales, marketing and communication plans related to the Licensed Product,iv)annually review the performance of the Licensed Product in the Lead Countries, and other countries as applicable,against the Business Plan and propose measures to improve performance as relevant and applicable; The Business Planshall provide sufficient details to enable an accurate assessment of the Licensed Product performance and of theresources allocated by Licensee to support its commercialization.The Joint Steering Committee shall meet a minimum of four times per calendar year at least once in person and otherwise byvideo- or telephone conference.The JSC shall solely have an advisory role to the Parties.Notwithstanding the above, in the event of a disagreement between the Parties on pricing strategy or on any other issuesdeemed material by one Party (the “Dispute”), the Dispute shall be escalated to the respective CEO’s of the Parties within 30 daysfollowing its written notification by the relevant Party to the other Party.The content of Licensee’s public communications on NLS, including its strategies, objectives, plans, management team, board ofdirectors, shareholders, finances, product portfolio, intellectual property rights and patents, on the Licensed Product, its revenueand share potential, data, brand and any forward-looking statements claims shall be pre-approved by NLS.11.CommercializationSubject to Article 10.3 above, Eurofarma shall be in charge and solely responsible for any pre-marketing, marketing, selling, warehousing,handling, distributing and all other commercial activities in relation to the Licensed Product in the countries of the Territory and theseactivities shall be determined by Eurofarma at its sole discretion and expenses, provided that Eurofarma shall use commercially reasonableefforts to commercialize the Licensed Product in the Lead Countries as a priority and in the other countries of the Territory.12Source: NLS PHARMACEUTICS LTD., F-1, 2/28/2020License and Development AgreementThe Licensee shall use best commercial efforts to make the first commercial sale of the Licensed Product in the Territory within twelve (12)months after receipt of marketing authorization in a given country of the Territory.12.SupplyNLS will supply Eurofarma with the finished Licensed Product based on its COGS. The Parties will enter in due time into a separatemanufacturing and supply agreement concerning the Licensed Product, with the possibility of tech-transfer during the term of theAgreement.13.Property rights to Intellectual PropertyBoth Parties acknowledge that all Intellectual Property existing at the Effective Date shall be and remain the sole property of the Licensor.All right, title and interest in and to any Developed Intellectual Property shall vest in and belong to the Licensor. The Licensee shallexecute and deliver all reasonably necessary signatures and/or documents and take any further steps (or have his employees, agents andofficers do the same) to the extent necessary to make any Developed Intellectual Property the sole property of the Licensor.The Licensee shall have right to use the Developed Intellectual Property for exploiting its rights granted in this Agreement until itsexpiration or termination as set forth in Article 19 hereunder.Licensee Know-how shall belong to the Licensee. The Licensee hereby grants to the Licensor an irrevocable, non-exclusive, royalty-free,perpetual, worldwide license to use of any Licensee Know-how.14.Prosecution of Infringements of Intellectual Property14.1.NoticeEither Party shall give notice to the other Party of any actual or suspected infringement of the Intellectual Property or theDeveloped Intellectual Property or any unlicensed activity, misuse or unauthorized disclosure of the same by any third party inthe Territory as soon as reasonably practicable following such Party becoming aware of it.14.2.ActionIn the event of any actual or suspected third party infringement of the Intellectual Property or the Developed Intellectual Propertyin the Territory, NLS may take at its sole discretion any steps (including legal action) to prosecute the infringement. Licensee shallon request support NLS in all activities which involve the protection of the Intellectual Property and the Developed IntellectualProperty and to prosecute the infringement.From the date of notice of a potential infringement, NLS shall have 5 (five) days to communicate to Eurofarma whether it will takeactions against such potential infringements. If NLS resolves not to take any such action, the Licensee shall have the right, butnot the obligation, to take all activities and steps to protect the Intellectual Property and the Developed Intellectual Property inthe Territory, provided however, that the Licensee shall not accept pay, settle or compromise any such claim or proceedingswithout the prior written consent of NLS.13Source: NLS PHARMACEUTICS LTD., F-1, 2/28/2020License and Development Agreement14.3.InformationThe Party in charge of the respective prosecution and legal action shall keep the other Party promptly and fully informed anddocumented as to the progress of any action.15.Representations and Warranties15.1.Licensor Representations and WarrantiesLicensor represents and warrants that each of the representations and warranties set out below are true and accurate in allrespects:a)Authority and capacityThe Licensor has the right to enter into this Agreement and any agreement or document referred to herein and performits obligations hereunder, including granting the licences under Article 2.b)Financial SituationThe Licensor has not committed an act of bankruptcy, proposed a compromise or arrangement to its creditors generally,had any petition in bankruptcy filed against it, filed a petition or undertaken any action proceeding to be declaredbankrupt, to liquidate its assets or to be dissolved.c)Intellectual PropertyTo the best of Licensor’s knowledge(i)Licensor has good, unrestricted and merchantable title to the Intellectual Property licensed to the Licenseehereunder;(ii)no part of the Intellectual Property licensed to the Licensee hereunder has been unlawfully copied from thirdparty materials;(iii)the use of the Intellectual Property will not infringe any third party intellectual property rights.d)Regulatory ComplianceTo the best of Licensor’s knowledge there is no hearing, investigation or audit of any regulatory authority alleging anyregulatory potential or actual non-compliance by Licensor or the Licensed Product under any applicable law or a lack ofsafety at the Effective Date.15.2.Licensee Representations and WarrantiesLicensee represents and warrants that each of the representations and warranties set out below are true and accurate in allrespects:a)Authority and CapacityThe Licensee has the right to enter into this Agreement and any agreement or document referred to herein and toperform its obligations hereunder.14Source: NLS PHARMACEUTICS LTD., F-1, 2/28/2020License and Development Agreementb)Financial SituationThe Licensee is not insolvent and has not committed an act of bankruptcy, proposed a compromise or arrangement to itscreditors generally, had any petition in bankruptcy filed against it, filed a petition or undertaken any action proceedingto be declared bankrupt, to liquidate its assets or to be dissolved.c)Regulatory ComplianceThe Licensee is able to obtain and hold a MA for the Licensed Product under the laws of each country of the Territoryand has (or will own at the time of the Launch in that country) any license required under the applicable law to import,sell and market the Licensed Product in the respective country.d)Intellectual PropertyThe Licensee has made all inspections and investigations of the Intellectual Property deemed necessary and desirableby the Licensee and it has made its own evaluation of the Intellectual Property, except any evaluation on non-infringement or validity of such rights, which is not the responsibility of Licensee.15.3.Other Representations and WarrantiesSave of the representations and warranties given in Article 15.1 the Licensor makes no further representation or warranty, eitherexpress, implied or statutory, written or oral, and any claims, regardless of their legal basis and nature, are, to the fullest extentpermissible by law, hereby excluded (unless such claims arise under the representations and warranties of Licensor) and theLicensee waives any such claim or right other than in respect of the Representations and Warranties of the Licensor.This exclusion or waiver applies in particular to:a)any projection, forecast, other forward-looking statement relating to the Licensed Product;a)any success, profitability, value, commercial marketability or competitiveness of any product at the market or itseligibility for reimbursement by any social security institutions, governmental bodies, statutory health insurances andthe like;b)any expectation or statement made that any future application for a MA will be granted;c)the extent, duration and validity of any MA, e.g. that any MA will be granted or that a granted MA will not be varied,suspended, revoked, withdrawn or cancelled or otherwise declared invalid by any competent regulatory authority in theTerritory;d)the quality, safety or efficacy of any product and other characteristics of any product;e)the presence or absence of any future deficiencies.Accordingly, save as expressly set out in this Agreement, the Licensee shall not be entitled to terminate this Agreement orexercise any right or remedy which would have a similar effect, or to claim damages from the Licensor.16.Liability and LimitationsEither Party shall only be liable for direct losses incurred by the other Party as a direct consequence of a negligent or intentional breach ofthis Agreement by such liable Party, and shall not be liable for any punitive or indirect damages, losses caused by business interruptions,loss of revenues, loss of profit, damages and loss of goodwill, or any reputational damages, and both Parties waive any claims to suchlosses.15Source: NLS PHARMACEUTICS LTD., F-1, 2/28/2020License and Development AgreementIn addition, neither Party shall be liable for any claim under this Agreement which is capable of remedy, unless and until the other Partyhas given such Party written notice containing full details of the breach and such Party has failed to remedy the breach within sixty (60)days of receipt of the notice.17.Indemnities17.1.Indemnities by the LicensorWithout prejudice to any other provision of this Agreement, the Licensor shall indemnify, defend and hold harmless the Licenseefrom and against all liabilities, claims, demands, obligations, fines, penalties, judgements, losses or damages whatsoever(including without limitation, court costs, amounts paid in settlement and any legal, accounting and other expert fees andexpenses reasonably incurred) (collectively “Losses”) suffered, incurred, sustained by or imposed on the Licensee resulting fromor arising out of:a)any breach of the representations and warranties made by the Licensor;b)any non-performance or breach of any of the Licensor’s obligations under this Agreement.17.2.Indemnities by the LicenseeWithout prejudice to any other provision of this Agreement, Licensee shall indemnify, defend and hold harmless Licensor fromand against all Losses suffered, incurred, sustained by or imposed upon Licensor resulting from or arising out of:a)any breach of the representations and warranties made by the Licensee;b)any non-performance or breach of any of the Licensee’s obligations under this Agreement.17.3.Third party claimsIf any claim is brought against a Party entitled to the benefit of an indemnity set out in this Agreement (the “Indemnified Party”)by any third party which is likely to result in a claim against the other Party who has given an indemnity under this Agreement(the “Indemnifying Party”), the Indemnified Party shalla)give notice of such third party claim to the Indemnifying Party as soon as reasonably practicable in reasonable detail,including a reasonable explanation of why the Indemnified Party assumes that it is entitled to indemnification under thisAgreement;b)keep the Indemnifying Party promptly and fully informed and documented as to the progress of any such claim;c)subject to the Indemnified Party being entitled to employ its own legal advisors take all reasonable steps as to minimiseor resolve such liability or dispute and, upon request by the Indemnifying Party, allow the Indemnifying Party to lead ordirect the proceedings;d)cooperate with all reasonable requests of the Indemnifying Party in relation to such claim; ande)not accept, pay, settle or compromise any such claim without the prior written consent of the Indemnifying Party (suchconsent not to be unreasonably withheld, delayed or conditioned).16Source: NLS PHARMACEUTICS LTD., F-1, 2/28/2020License and Development Agreement18.Confidentiality18.1.Confidentiality Obligationsa)Confidential Information shall mean any information that (i) is not publicly known (ii) has been imparted incircumstances in which the recipient ought reasonably to have known that the information had been imparted inconfidence. This includes especially but not exclusively the information described in the clauses 18.1 b), c) and d).b)Each Party undertakes to maintain confidentiality as regards the execution and terms of this Agreement, and to abstainfrom disclosing the existence of this Agreement, its contents and all information provided to it by the other Party inconnection with the negotiation of this Agreement without prior written approval of the other Party.c)The Licensee shall maintain confidentiality with regard to the Dossier and Know-how and any operations, processes,product information, product formulations, information regarding applications and submissions, know-how, designs,trade secrets, product plans, product development efforts, other commercial and product data, software, prototypes,samples and/or data sets related thereto, and any information or analysis derived from Confidential Information. For theavoidance of any doubt, the confidentiality of the Dossier and Know-how shall only apply to information that at thetime of assessment is actually considered to be confidential, and not, under any circumstances, the information thatlawfully is or has become available to the public.d)The Licensee shall protect any Know-how and any data as Confidential Information and shall not use the Know-howand data for any purpose except as expressly licensed hereby and in accordance with the provisions of this Agreement.Each Party (the “Receiving Party”) undertakes:(i.)to maintain as secret and confidential all Confidential Information obtained directly or indirectly from the other Party (the“Disclosing Party”) in the course of this Agreement and to respect the Disclosing Party’s rights therein;(ii.)to use such Confidential Information only for the purposes of this Agreement; and(iii.)to disclose such Confidential Information only to those of its employees, contractors, and sub-licensees pursuant tothis Agreement (if any) to whom and to the extent that such disclosure is reasonably necessary for the purposes of thisAgreement.18.2.Exceptions to ObligationsThe provisions of clause 18.1 shall not apply to Confidential Information that the Receiving Party can demonstrate by reasonable,written evidence;(i.)is or has become generally available to the public other than as a direct or indirect result of a disclosure by the ReceivingParty or any of its representatives; or(ii.)was, prior to its receipt by the Receiving Party from the Disclosing Party, in the possession of the Receiving Party and atits free disposal; or(iii.)is subsequently disclosed to the Receiving Party without any obligations of confidence by a Third Party who has notderived it directly or indirectly from the Disclosing Party; or(iv.)was or is developed by or on behalf of the Receiving Party independently of the Disclosing Party’s ConfidentialInformation; or17Source: NLS PHARMACEUTICS LTD., F-1, 2/28/2020License and Development Agreement(v.)the Receiving Party is required to disclose to the courts of any competent jurisdiction, or to any government regulatoryagency, or financial authority, provided that the Receiving Party shall (i) inform the Disclosing Party as soon as isreasonably practicable, and (ii) at the Disclosing Party’s request seek to persuade the court, agency, or authority to havethe information treated in a confidential manner, where this is possible under the court, agency, or authority’sprocedures.18.3.Survival of Confidentiality ObligationsThe confidentiality obligations provided in this Article shall survive any termination or expiry of this Agreement for period of ten(10) years.19.Term and Termination19.1.TermThis Agreement will come into effect on the Effective Date and shall continue in full force for ten (10) years from the Launch (the“Initial Term”), or the date of expiry of the last valid patent of the Licensed Product, whichever comes later, subject to clauses19.2, 19.3, 19.4 and 19.5 hereunder.By mutual agreement of the Parties, the Initial Term may be extended by successive periods of three (3) years.If any relevant registration is not successfully reached with regards to any extension of the Agreement, the Parties shallcooperate and negotiate on arm’s length basis in order to obtain a suitable solution and achieve a proper agreement that enablesthe Parties to fully comply with the rights, obligations and commitments herein set forth.19.2.Termination for Change of ControlIn the event of a Change of Control of the Licensee, the Agreement may be terminated by Licensor with immediate effect withoutany compensation to Licensee or to any other parties.In the event of a Change of Control of the Licensor, the Agreement may be terminated by Licensee. In case of termination of theAgreement, NLS and Eurofarma shall immediately work on a transition out plan, with activities and timelines agreed by the Partiesto ensure a proper handover of the Licensed Product so that its market position and the obligations to prescribers, patients andregulatory authorities are fulfilled in accordance with Eurofarma best practices.19.3.Termination for Bankruptcy, Liquidation and similar proceedingsThis Agreement may be terminated by either Party, effective upon notice following the expiry of the cure period describedhereafter, upon the filing or institution of any bankruptcy, reorganization, liquidation or receivership proceedings of the otherParty, or upon the failure by the other Party for more than ninety (90) days to discharge or obtain the dismissal of any suchactions filed against it. Such termination shall be effective upon receipt of notice from the affected Party.19.4.Early Termination for Material BreachIf either of the Parties fails to perform or violates any material term of this Agreement (the “Breaching Party”), then the otherParty (the “Other Party”) may give written notice of default (“Notice of Default”) to the Breaching Party.18Source: NLS PHARMACEUTICS LTD., F-1, 2/28/2020License and Development AgreementIf Licensee is the Breaching Party and fails to cure the default within sixty (60) calendar days upon receipt of the Notice ofDefault, the Licensor has the right to terminate this Agreement with immediate effect by written notice (“Notice of Termination”)to the Breaching Party.If Licensor is the Breaching Party and fails to cure the default within sixty (60) calendar days upon receipt of the Notice ofDefault, the Licensee has the right to terminate this Agreement with immediate effect by written notice (“Notice of Termination”)to the Breaching Party and shall be paid by Licensor an indemnity corresponding to the fair market value of the expecteddiscounted cash flows of Licensee over the remaining lifetime of this Agreement.19.5.Early Termination by the LicensorThe Agreement may be terminated by NLS according to Article 19.4 in case Eurofarma fails to use commercially reasonable effortsto obtain a MA and to commercialize the Licensed Product in the Lead Countries, provided that the Supplemental Data, if any,was provided to Eurofarma.If Eurofarma has not made the first commercial sale within twelve (12) months after receipt of the MA in a Lead Country of theTerritory, not for reasons outside of its control, or if Eurofarma has failed to use reasonable commercial efforts to meet the annualobjectives of the most updated Business Plan during the Term, which may be amended by Eurofarma from time to time andaccepted by NLS, then NLS may, upon sixty (60) days prior written notice to Eurofarma (unless Eurofarma makes such firstcommercial sale within such sixty-day period), terminate the rights granted to Eurofarma with respect to the Licensed Product insuch country.19.6.Early Termination by the Licenseei)Eurofarma may terminate the Agreement upon ninety (90) days prior written notice to NLS in case the US SupplementalData to support the Dossier for Brazil is not or cannot be provided by NLS within the time limit agreed by the Parties orcannot be generated as part of the Local Supplemental Data for Brazil.ii)Eurofarma may terminate the Agreement in case the activities conducted by NLS under article 5, paragraphs a), b) and c)do not allow the Licensed Product to be approved by the US FDA.iii)Eurofarma may terminate the Agreement in case the Licensed Product fails to receive a MA from the US FDA or a MA isnot granted on the Licensed Product in any of the Lead Countries despite reasonable commercial efforts by Eurofarma toseek and obtain such MA.iv).Eurofarma shall have the right to terminate the Agreement in case of fundamental changes in the market, competitive andeconomic conditions, outside of the Parties control, at the time of the launch of the Licensed Product in the territorywhich would make its commercialization not economically viable and provided that the Parties after good faith efforts failto agree on an alternative plan to address this situation within 3 months following the notification by Eurofarma to NLSof its decision to terminate the Agreement under this clause.19Source: NLS PHARMACEUTICS LTD., F-1, 2/28/2020License and Development Agreement19.7.Consequences of Expiration or TerminationThe expiration or termination of the Agreement shall have the following consequences:(i)The Licensee shall cease to use the License and cease to conduct any activities that would require the License, unlessexplicitly stated otherwise in this Article.(ii)Licensee or Affiliates or Distributors may sell off all previously purchased Licensed Products still in their warehouseswithin a period of six (6) months of the effective date of such termination (the “Sell-Off Period”) provided that the sale ofsuch Licensed Products by Licensee or Affiliates or Distributors of the Licensee shall be subject to the terms of thisAgreement, including but not limited to the rendering of reports and payment of royalties required under thisAgreement.(iii)Promptly upon the request of Licensor, the Licensee shall, at the Licensor’s sole discretion and election for each countryof the Territory and each Licensed Product either withdraw or transfer all Marketing Authorizations in the Territory tothe Licensor (or to a third party as the Licensor directs). Licensee shall take the required steps without any delay and thewithdrawal or transfer shall be completed in maximum 90 days after the notification of the request; if the Licensor doesnot decide and inform within this period to whom the Marketing Authorizations and documents shall be transferred,then the Licensee shall have no obligation to keep them active. If a Marketing Authorization has been applied for, butnot yet been granted in any country of the Territory, the same shall apply to the applicant status.(iv)The Licensee shall hand over to the Licensor any and all documents related to the regulatory status or containingIntellectual Property or Confidential Information of Licensor.(v)Termination shall not relieve either Party of its accrued obligations under this Agreement.(vi)With the exception of termination in case of material breach of its obligations by Licensor according to Article 19.4, upontermination, or early termination by the Licensee according to Article 19.6, Licensee shall pay Licensor any unpaid sums(fees, milestone payments, royalties, etc.) related to the Agreement.20.General Provisions20.1.AmendmentsThis Agreement may only be modified or amended by a document duly signed by all Parties. Any provision contained in thisAgreement may only be waived by a document duly signed by the Party waiving such provision.20.2.NoticesAll notices or other communications to be given under or in connection with this Agreement shall be made in writing and shall bedelivered by registered mail or overnight courier service to the address that is mentioned on the cover page of this Agreement orsubsequently communicated in writing.All notices shall become effective on the day of their reception by the receiving Party, or if the receiving Party refuses itsacceptance or does not collect it from the competent post office or mail service, on the date of the refusal.20.3.Severability / Good FaithShould any part or provision of this Agreement be held to be invalid by any competent court, governmental or administrativeauthority having jurisdiction, the other provisions of this Agreement shall nonetheless remain valid. In this case, the Parties shallendeavour to negotiate a substitute provision that best reflects the economic intentions of the Parties without beingunenforceable, and shall execute all agreements and documents required in this connection. The same shall apply if and to theextent that this Agreement is found to contain any gaps or omissions.20Source: NLS PHARMACEUTICS LTD., F-1, 2/28/2020License and Development Agreement20.4.No WaiverThe failure of any of the Parties to enforce any of the provisions of this Agreement or any rights with respect thereto shall in noway be considered as a waiver of such provisions or rights or in any way affect the validity of this Agreement.20.5.No AssignmentThis Agreement may not be assigned or otherwise transferred, nor may any right or obligations hereunder be assigned ortransferred, by either Party without the prior written consent of the other Party; provided, however, that Licensor may, withoutsuch consent, assign this Agreement and its rights and obligations hereunder, in whole or in part, to an Affiliate or in connectionwith the transfer or sale of all or substantially all of its assets related to the Licensed Product or the business relating thereto, orin the event of its merger or consolidation or change in control or similar transaction. Licensor shall however refrain from anysuch permitted assignment if such permitted assignment is reasonably able to jeopardize Licensee’s business of LicensedProduct in the Territory.20.6.AppendicesAll Appendices form an integral part of this Agreement.20.7.Public AnnouncementsNo press releases or other public announcement concerning this Agreement shall be made by either Party unless the form andtext of such announcement shall first have been approved by the other Party, except for any announcements based on reportingduties under applicable laws and regulations or stock exchange regulations.21.Governing Law and JurisdictionThis Agreement shall be governed by and construed in accordance with the substantive laws of the Netherlands, excluding its rules ofconflicts of law and the United Nations Convention on Contracts for the International Sale of Goods dated 11 April 1980 (CISG), asamended from time to time.All disputes arising out of or in connection with the present Agreement, including disputes on its conclusion, binding effect, amendmentand termination, shall be finally resolved by binding arbitration in accordance with the Rules of Arbitration of the International Chamber ofCommerce (“ICC”) by one or more arbitrators appointed in accordance with the said rules and experienced in the pharmaceutical business.The place of Arbitration shall be in The Hague, Netherlands, or in a place otherwise mutually agreeable. The arbitration shall be conductedin English.21Source: NLS PHARMACEUTICS LTD., F-1, 2/28/2020License and Development AgreementIN WITNESS WHEREOF, the Parties have caused this Agreement to be duly executed in two counterparts on the date first written above, wherebyeach Party shall execute and initialize one counterpart, each of which when so executed and delivered shall be an original but shall not be effectiveuntil each Party has executed at least one counterpart, but all counterparts shall together constitute one and the same agreement.NLS-1 Pharma AG/s/ Ronald Hafner/s/ Alex ZwyerRonald HafnerAlex ZwyerChairman of the BoardCEO Member of the Board of DirectorsDate:Eurofarma Laboratórios S.A./s/ Julíana Mazza Reîs/s/ Martha PennaName:Julíana Mazza ReîsName:Martha Pennatitle:Eurofarma Laboratórios S.A.title:Vice Presîdente InovaçäoDíretora de Gestào de PortfólÎo e LÎcençasDate:Witnesses:/s/ Bruno C.Z. Baptista/s/ Walker LahmannName:Bruno Castagnoli Zilli BaptistaName:Walker LahmannId.:Portfolio Management Licensing CoordinatorId:Executive Director22Source: NLS PHARMACEUTICS LTD., F-1, 2/28/2020License and Development AgreementTable of AppendicesNumberNameAppendix A[Template for Licensee Reports]Appendix BPreliminary Business Plan23Source: NLS PHARMACEUTICS LTD., F-1, 2/28/2020License and Development AgreementAppendix A - [Template for Licensee Reports] to be provided by NLS to Eurofarma within 60 days following the effective date of signature of theAgreement24Source: NLS PHARMACEUTICS LTD., F-1, 2/28/2020License and Development AgreementAppendix B Preliminary Business PlanSales Forecast Latin America in units (monthly treatments, considering both adult and pediatric indications)Forecast in UnitsYEAR 1YEAR 2YEAR 3YEAR 4YEAR 5YEAR 6YEAR 7YEAR 8YEAR 9YEAR10TOTALBRAZIL67.435154.809232.214348.321435.401522.481548.605576.035587.556599.307 4.072.162REST OF LATAM21.93171.105135.482206.698259.783299.791343.867327.768287.040276.346 2.229.813TOTA LATAM89.366 225.914 367.696 555.019 695.184 822.272 892.472 903.803 874.596 875.653 6.301.97425Source: NLS PHARMACEUTICS LTD., F-1, 2/28/2020